Table 5.
Unadjusted estimates of health service outcomes and mortality between those with OUD using OAT, those with OUD using naltrexone, those with OUD not using treatment, and those without OUD among COVID-19 positive patients.
| OUD using OAT n (%)1 | OUD using naltrexone n (%) | OUD not using treatment n (%) | No OUD n (%) | p-value3 | |
|---|---|---|---|---|---|
| Total | 84 | 17 | 912 | 51,299 | |
| Hospitalized | 74 (88.1) | 17 (100.0) | 789 (86.5) | 26,833 (52.3) | <0.001 |
| Maximum LOS (Days)2 | 5.9 (2.4–11.8) | 13.4 [3.1–27.2] | 6.0 (2.3–12.1) | 1.4 (0.1–6.3) | <0.0014 |
| Invasive Ventilator Dependence | 11 (13.1) | 6 (35.3) | 171 (18.8) | 5948 (11.6) | <0.001 |
| Death | 4 (4.8) | 2 (11.8) | 124 (13.6) | 4555 (8.9) | <0.001 |
1
n (column%) unless otherwise noted;.
2
median (Q1-Q3), maximum LOS is restricted to only hospitalized patients (n = 27,713).
3
Chi-Square test unless otherwise noted;.
4
Kruskall–Wallis test.